- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Spinal muscular atrophy (SMA)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 1.1MB)
Onasemnogene abeparvovec – November 2025
Onasemnogene abeparvovec: Pack containing 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 5.5 mL and 1 vial solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL Pack containing 2 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL Pack containing 3 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL Pack containing 4 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL Pack containing 5 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL Pack containing 6 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL Pack containing 7 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL Pack containing 8 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL Pack containing 9 vials solution for I.V. infusion 20 trillion vector genomes per mL, 8.3 mL; Zolgensma® - November 2025
